164 related articles for article (PubMed ID: 34689234)
1. PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival.
Núñez KG; Sandow T; Fort D; Hibino M; Wright P; Cohen AJ; Thevenot PT
Cancer Immunol Immunother; 2022 Jun; 71(6):1453-1465. PubMed ID: 34689234
[TBL] [Abstract][Full Text] [Related]
2. Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization - Implications in treatment outcomes.
Núñez KG; Sandow T; Gimenez J; Hibino M; Fort D; Cohen AJ; Thevenot PT
Eur J Cancer; 2024 Jan; 196():113442. PubMed ID: 37988841
[TBL] [Abstract][Full Text] [Related]
3. Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy.
Núñez KG; Sandow T; Lakey MA; Fort D; Cohen AJ; Thevenot PT
Front Oncol; 2022; 12():809860. PubMed ID: 35785174
[TBL] [Abstract][Full Text] [Related]
4. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
Wang H; Huang H; Liu T; Chen Y; Li J; He M; Peng J; Liang E; Li J; Liu W
Front Immunol; 2024; 15():1325330. PubMed ID: 38404585
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
8. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
10. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.
Hung YP; Shao YY; Lee JM; Hsu C; Hsu CH; Yang MH; Chao Y
J Chin Med Assoc; 2021 Feb; 84(2):144-150. PubMed ID: 33433132
[TBL] [Abstract][Full Text] [Related]
11. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
Sandow T; Pavlus J; Field D; Lacayo E; Cohen E; Lynskey G; Caridi T; Buckley D; Cardella J; Kallakury B; Spies J; Kim AY
J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
[TBL] [Abstract][Full Text] [Related]
12. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
14. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
15. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
Cucchetti A; Serenari M; Sposito C; Di Sandro S; Mosconi C; Vicentin I; Garanzini E; Mazzaferro V; De Carlis L; Golfieri R; Spreafico C; Vanzulli A; Buscemi V; Ravaioli M; Ercolani G; Pinna AD; Cescon M
J Hepatol; 2020 Aug; 73(2):342-348. PubMed ID: 32201284
[TBL] [Abstract][Full Text] [Related]
16. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
17. Absolute lymphocyte count recovery at 1 month after transplantation predicts favorable outcomes of patients with hepatocellular carcinoma.
Zheng Z; Lin B; Zhang J; Yang Z; Xie H; Zhou L; Zhang M; Zheng S
J Gastroenterol Hepatol; 2015 Apr; 30(4):706-11. PubMed ID: 25238140
[TBL] [Abstract][Full Text] [Related]
18. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.
Cucchetti A; Cescon M; Bigonzi E; Piscaglia F; Golfieri R; Ercolani G; Cristina Morelli M; Ravaioli M; Daniele Pinna A
Liver Transpl; 2011 Nov; 17(11):1344-54. PubMed ID: 21837731
[TBL] [Abstract][Full Text] [Related]
19. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Chen Y; Han Q; Lv Y; Liu Z
Medicine (Baltimore); 2016 Dec; 95(52):e5749. PubMed ID: 28033288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
